证券代码：688505 证券简称：复旦张江 公告编号：临 2025-015 上海复旦张江生物医药股份有限公司 关于召开2024年度股东周年大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024年度股东周年大会 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 26 日 至2025 年 6 月 26 日 股东大会召开日期：2025年6月26日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 6 月 26 日 14 点 00 分 召开地点：上海市浦东新区碧波路 699 号上海博雅酒店一楼会议室 （五） 网络投票的系统、起止日期和投票时间。 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 ...

股票代码：688505 股票简称：复旦张江 编号：临2025-013 上海复旦张江生物医药股份有限公司 第八届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 经与会监事审议，做出如下决议： （一）审议通过《关于公司 2025 年第一季度报告的议案》 监事会认为：《公司 2025 年第一季度报告》的编制及审议程序均符合法律、 法规、规范性文件和《公司章程》的要求，格式和内容符合上海证券交易所的各 项规定，内容真实、准确、完整地反映出公司本报告期经营管理和财务状况，不 存在任何虚假记载、误导性陈述或者重大遗漏。在作出本决议之前，未发现参与 2025 年第一季度报告编制和审议的人员存在违反相关制度和规定的行为。因此， 同意《公司 2025 年第一季度报告》相关内容。 表决情况：3 票同意，0 票反对，0 票弃权。 （二）审议通过《关于使用暂时闲置募集资金进行现金管理的议案》 上海复旦张江生物医药股份有限公司（以下简称"公司"或"本公司"）第八届 监事会第九次会议于 2025 年 ...

上海复旦张江生物医药股份有限公司2025 年第一季度报告 公司 H 股代码：01349 证券简称：复旦张江 上海复旦张江生物医药股份有限公司 2025 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人赵大君、主管会计工作负责人薛燕及会计机构负责人（会计主管人员）章雯保证季度 报告中财务信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比上 | | | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期 | 年同期增减变 | | | | | 动幅度(%) | | 营业收入 | 179,906,064 | 147,647,109 | 21.85 | | 归属于上市公司股东的净利润 | 2,665,11 ...

Financial Performance - Total revenue for the year ended December 31, 2024, was RMB 709,405,000, a decrease of 16.6% compared to RMB 850,733,000 in 2023[5] - Profit before tax for 2024 was RMB 5,458,000, down 94.4% from RMB 97,528,000 in 2023[5] - Net profit attributable to shareholders for 2024 was RMB 39,734,000, a decline of 63.4% from RMB 108,627,000 in 2023[5] - The company's revenue decreased by 17% year-on-year during the reporting period[34] - The company's revenue for the fiscal year 2024 was approximately RMB 709,405 thousand, a decrease of 17% compared to RMB 850,733 thousand in 2023, primarily from core business operations[55] - Revenue from the sale of medical and diagnostic products in 2024 was RMB 709,378 thousand, accounting for 99.9963% of core business revenue, also down 17% from RMB 850,564 thousand in 2023[57] - The net profit for 2024 was approximately RMB 39,434 thousand, a decline of about 64% from RMB 108,450 thousand in 2023, with a net profit margin of 6% compared to 13% in the previous year[67] - Sales revenue from Aira® decreased by 13% compared to the same period last year[35] - Sales revenue from Libod® declined by 28% year-on-year[36] - Sales revenue from Fumida® dropped by 4% compared to the previous year[37] Assets and Liabilities - Total assets as of December 31, 2024, were RMB 2,586,503,000, a decrease of 10.1% from RMB 2,876,688,000 in 2023[6] - Total liabilities for 2024 were RMB 281,226,000, down 45.4% from RMB 518,124,000 in 2023[6] - The company has a cash and cash equivalents balance of approximately RMB 1,056,286 thousand as of December 31, 2024, down from RMB 1,195,896 thousand as of December 31, 2023[78] - The company has no outstanding bank financing as of December 31, 2024, indicating a debt-free status[75] Research and Development - The company plans to strategically focus on the development and industrialization of photodynamic therapy technology, leveraging its competitive advantages in this area[11] - The company aims to accelerate the research and industrialization of antibody-drug conjugates (ADCs), despite the competitive landscape in this field[11] - The company has established multiple technology platforms, including gene engineering and nanotechnology, to support ongoing drug development projects[10] - The company emphasizes a balanced approach between innovation and industrialization, as well as research and marketing[12] - Research and development expenses increased by 29% to RMB 314,162 thousand in 2024, up from RMB 243,763 thousand in 2023, reflecting a commitment to ongoing R&D projects[60] - The company is focusing on research and development in its advantageous fields, including photodynamic technology and nanotechnology[43] - The company is committed to continuous innovation and the development of new projects to provide valuable treatment options for patients[43] - The company has made significant progress in R&D, including the initiation of clinical trials for multiple drug candidates targeting various cancers and diseases[51] Clinical Trials and Product Development - The current pipeline includes photodynamic therapy (PDT) and photodynamic diagnosis (PDD), targeting conditions such as cervical precancerous lesions and breast cancer[14] - The photodynamic treatment for severe acne using aminolevulinic acid (ALA) has completed Phase II clinical trials, with results presented at the European Society for Dermatological Research meeting[20] - The clinical study for ALA in treating cervical precancerous lesions has completed Phase II trials and will soon enter Phase III trials, aiming for new indication registration[19] - The company is developing intraoperative molecular imaging (IMI) technology for real-time tumor visualization during surgeries, particularly for gliomas and bladder cancer[16] - The clinical trial for the use of aminolevulinic acid hydrochloride granules in non-muscle invasive bladder cancer (NMIBC) surgery has received approval, with the first subject enrolled during the reporting period[22] - The clinical trial for the use of aminolevulinic acid hydrochloride granules in breast-conserving surgery for breast cancer has also received approval, addressing a significant clinical need in real-time tumor margin assessment[24] - The global first photodynamic drug for treating infantile hemangioma, Heimofen, has completed the enrollment of the first subject in its Phase II clinical trial in the U.S.[25] - The first antibody-drug conjugate (ADC) developed by the company, targeting CD30, has had its Phase I clinical trial results presented at the American Society of Hematology meeting, although its advancement has been temporarily paused due to strategic considerations[27] - The second ADC targeting Trop2 for triple-negative breast cancer and other tumors has completed the enrollment of the first subject in its Phase III clinical trial for triple-negative breast cancer[28] Market and Industry Trends - The global pharmaceutical market is expected to exceed USD 1.1 trillion in 2024, with a projected compound annual growth rate of 3-6% until 2026[49] - By 2025, the Chinese pharmaceutical market is estimated to reach RMB 2.1 trillion, with the biopharmaceutical market expected to account for 48% of this[49] - The global biopharmaceutical industry is undergoing profound changes driven by new technologies, with a shift towards patent cooperation and mergers and acquisitions[50] - The Chinese pharmaceutical industry is a strategic emerging industry, with a focus on accelerating the development of innovative drugs and biomanufacturing as new growth engines[131] - The market for broad skin disease treatment and care in China grew from RMB 300.4 billion in 2017 to RMB 471.8 billion in 2021, with a compound annual growth rate of 11.95%[132] - The incidence of skin diseases is increasing, with a significant rise in the number of patients and treatment visits, indicating a growing market demand[132] Corporate Governance and Financial Policies - The company has established a robust corporate governance structure to enhance transparency and accountability, thereby protecting shareholder interests and boosting investor confidence[190] - The company has implemented a stable and proactive profit distribution policy since 2015, prioritizing cash dividends when profits are available[170] - The company plans to maintain a cash dividend ratio of no less than 10% of the distributable profits in the first three years post-IPO[170] - The company has a conservative financial policy to ensure that its assets do not bear unnecessary risks, with no outstanding bank loans as of the reporting date[79] Employee and Management Information - The employee cost for the year 2024, including director remuneration, was RMB 232,115 thousand, compared to RMB 238,468 thousand in 2023[82] - The company has not provided employee dormitories during the year, and details regarding housing provident funds are included in the financial statements[188] - The company has purchased liability and indemnity insurance for directors and senior management, covering responsibilities related to both H-shares and A-shares listings[199]

Financial Performance - The company's operating revenue for the first quarter was RMB 179,906,064, representing a year-on-year increase of 21.85% compared to RMB 147,647,109 in the same period last year[5]. - Net profit attributable to shareholders was RMB 2,665,114, reflecting a growth of 13.53% from RMB 2,347,396 in the previous year[5]. - Net profit for Q1 2025 was RMB 2,581,403, compared to RMB 2,259,878 in Q1 2024, showing a growth of 14.2%[20]. Cash Flow - The net cash flow from operating activities decreased significantly by 84.34%, amounting to RMB 6,880,311, down from RMB 43,938,388 in the same period last year[5][10]. - For the first quarter of 2025, the net cash flow from operating activities was RMB 6,880,311, a decrease of 84.7% compared to RMB 43,938,388 in the first quarter of 2024[21]. - Total cash inflow from operating activities was RMB 238,939,006, down 2.9% from RMB 244,729,122 in the same period last year[21]. - Cash outflow from operating activities increased to RMB 232,058,695, up 15.5% from RMB 200,790,734 in the first quarter of 2024[21]. - The net cash flow from investing activities was -RMB 283,810,018, compared to -RMB 3,807,572 in the first quarter of 2024, indicating a significant increase in cash outflow[21]. - Cash inflow from investing activities totaled RMB 591,051,753, a decrease of 35.6% from RMB 919,724,441 in the previous year[21]. - Cash outflow from investing activities was RMB 874,861,771, down 5.3% from RMB 923,532,013 in the first quarter of 2024[21]. - The net cash flow from financing activities was -RMB 2,005,026, compared to -RMB 2,669,076 in the first quarter of 2024[21]. - The ending cash and cash equivalents balance was RMB 777,319,430, a decrease of 37.0% from RMB 1,233,394,449 at the end of the first quarter of 2024[21]. - The company received RMB 8,367,074 in other cash related to operating activities, an increase of 121.5% from RMB 3,769,626 in the first quarter of 2024[21]. - The company reported a cash flow impact from foreign exchange fluctuations of -RMB 31,466, compared to a positive impact of RMB 36,712 in the first quarter of 2024[21]. Research and Development - Research and development expenses totaled RMB 84,068,447, which is an increase of 31.00% compared to RMB 64,173,693 from the previous year[5][10]. - The ratio of R&D investment to operating revenue increased to 46.73%, up by 3.27 percentage points from 43.46% in the previous year[8]. - R&D expenses rose to RMB 84,068,447 in Q1 2025, compared to RMB 63,616,910 in Q1 2024, indicating a focus on innovation and product development[20]. Assets and Liabilities - Total assets at the end of the reporting period were RMB 2,531,022,514, a decrease of 2.14% from RMB 2,586,502,623 at the end of the previous year[8]. - The total assets as of March 31, 2025, amounted to RMB 2,531,022,514, a decrease from RMB 2,586,502,623 as of December 31, 2024[19]. - Total liabilities decreased to RMB 223,197,709 as of March 31, 2025, down from RMB 281,225,518 at the end of 2024[19]. - The total equity attributable to shareholders reached RMB 2,307,198,823 as of March 31, 2025, slightly up from RMB 2,304,567,412 at the end of 2024[19]. Shareholder Information - The company reported a total of 19,246 common shareholders at the end of the reporting period[13]. - The top ten shareholders held a combined total of 1,339,000,000 shares, representing significant ownership concentration[14]. Government Subsidies and Market Strategy - The company received government subsidies amounting to RMB 4,538,759, which are closely related to its normal business operations[7]. - The company plans to adjust its sales strategies and pricing for the drug Libao Duo® in response to changes in the national drug procurement landscape starting April 2025[17]. - The company is focusing on optimizing its marketing network and customer base in light of provincial medical insurance policies[17]. Credit Impairment - The company reported a significant increase in credit impairment losses, amounting to RMB 14,720,951 in Q1 2025, compared to a reversal of RMB 5,559,028 in Q1 2024[20].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 4 月 28 日（周一）至 5 月 7 日（周三）16:00 前登录上证 路演中心网站首页，点击"提问预征集"栏目或通过公司邮箱 ir@fd-zj.com 进行 提问。公司将在文字互动环节对投资者普遍关注的问题进行回答。 上海复旦张江生物医药股份有限公司（以下简称"公司"）已于 2025 年 3 月 28 日于上海证券交易所网站（www.sse.com.cn）披露了公司 2024 年年度报告， 为便于广大投资者全面深入地了解公司 2024 年度经营成果、财务状况，公司计 划于 2025 年 5 月 8 日（周四）15:00-17:00 参加 2024 年度科创板创新药行业集 体业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 股票代码：688505 股票简称：复旦张江 公告编号：临 2025-012 上海复旦张江生物医药股份有限公司关于参加 2024 年度科创板创新药行业集体业绩说明会的公告 本次业绩说明会以线上文字互动形式召 ...

医药板块持续走高 众生药业等多股涨停 智通财经4月22日电，午后医药板块持续走高，创新药方向继续领涨，众生药业、华森制药、富士莱涨 停，百利天恒、诺诚健华、新诺威、百济神州创历史新高，复旦张江、上海谊众、信立泰、热景生物等 涨幅靠前。消息面上，4月25日至4月30日，美国癌症研究协会（AACR）年会将在芝加哥召开。作为全 球规模最大的癌症研究会议之一，AACR年会一直是癌症领域最新研究成果的重要展示平台。 ...

Group 1 - The core stock price of Fudan Zhangjiang (688505) closed at 8.11 yuan, up 0.12% from the previous week, with a market cap of 8.583 billion yuan [1] - The company ranks 52 out of 152 in the chemical pharmaceutical sector and 1803 out of 5140 in the A-share market [1] - The company actively communicates with investors through various platforms to ensure transparency and timely disclosure of business progress [1][3] Group 2 - Fudan Zhangjiang focuses on innovative research and development in biomedicine, establishing multiple technology platforms including photodynamic technology and ADC drug development [1][3] - R&D expenses increased by approximately 70 million yuan compared to the same period last year, with several ADC drug projects entering clinical stages [1][3] - The FDA018 antibody-drug conjugate project has entered phase III clinical trials, while the FZ-AD005 antibody-drug conjugate project has entered phase I clinical trials [1] Group 3 - The company has entered into a structured deposit agreement with Shanghai Pudong Development Bank, investing a total of 220 million yuan [2][3] - The structured deposit product has a low-risk rating, with a term of 89 days and an expected annualized return of 0.85%-2.40% [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內容而產生或因依賴該等內容而 引致的任何損失承擔任何責任。 須予披露的交易 認購平安銀行結構性存款產品 在訂立平安銀行結構性存款產品協議時，就平安銀行結構性存款產品協議項下產品的認購金額而 言，一項或多項適用百分比率（定義見上市規則第 14.07 條）超過 5%但均低於 25%，故根據上市 規則第 14 章，该交易構成本公司之須予披露的交易，須遵守上市規則第 14 章有關申報及公告之 規定，惟獲豁免遵守獨立股東批准之規定。 概述 近日，本公司與平安銀行訂立平安銀行結構性存款產品協議，同意以日常營運產生的自有閑置資金 向平安銀行認購金額為人民幣 2.00 億元的結構性存款產品。 - 1 - 平安銀行結構性存款產品協議 | 期末價格區間 | 實際年化收益率 | | --- | --- | | 期末價格≥起始價格*110.00% | 2.40% | | 起始價格*110.00%>期末價格≥起始價格*94.50% | 2.30% | | 期末價格<起始價格*94.50% | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內容而產生或因依賴該等內容而 引致的任何損失承擔任何責任。 須予披露的交易 認購浦發銀行結構性存款產品 認購結構性存款產品 近日，本公司與浦發銀行訂立浦發銀行結構性存款產品協議，同意以日常營運產生的自有閑置資 金向浦發銀行認購總金額為人民幣 2.20 億元的結構性存款產品。 上市規則的涵義 在訂立浦發銀行結構性存款產品協議時，就浦發銀行結構性存款產品協議項下產品的認購金額而 言，一項或多項適用百分比率（定義見上市規則第 14.07 條）超過 5%但均低於 25%，故根據上市 規則第 14 章，该交易構成本公司之須予披露的交易，須遵守上市規則第 14 章有關申報及公告之 規定，惟獲豁免遵守獨立股東批准之規定。 -1- 上市規則之涵義 在訂立浦發銀行結構性存款產品協議時，就浦發銀行結構性存款產品協議項下產品的認購金額而言， 一項或多項適用百分比率（定義見上市規則第 14.07 條）超過 5%但均低於 25%，故根據上市規則 第 14 章，该交易構成本公司之須予披露的交易 ...